In an effort to further preserve residual acoustic hearing after cochlear implantation, it may be beneficial to incorporate anti-inflammatory agents into the electrode array for passive elution over a time course after implantation. This study aims to assess the ease and effectiveness of such an electrode design, and to assess the preliminary safety of use of such a device in the post-operative period. This study is a first-time-in-human study of the investigational device. In the first instance, the aim of the current investigation is to obtain first experience in use of a Combined Device in the adult clinical population, and to assess tools and techniques that may be considered in future clinical studies of similar devices.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
Standard Contour Advance electrode
The HEARing CRC
Melbourne, Victoria, Australia
Surgical feedback
Questionnaire used to obtain surgical feedback from experienced cochlear implant surgeons regarding the electrode design, and ease and effectiveness of surgery, when using the Combined Device as compared to the Contour Advance electrode
Time frame: During surgery
Safety of Combined Device
Monitoring of device related adverse events that occur during the study period, to assess the preliminary safety of the Combined Device
Time frame: Monitoring over 24 months
Electrode impedance
Time frame: Testing over 24 months
Electrically evoked compound action potential (ECAP)
Time frame: Testing over 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.